Table 3. Immunohistochemical Staining and Clinical Data Association.

Clinical data	N	COX-1 area expression; N (%)		p	COX-2 area expression; N (%)		p
		≤ 75% n = 60	> 75% n = 47		≤ 75% n = 33	> 75% n = 74
Age
≤ 60 years	79	47 (59.5)	32 (40.5)	0.23	28 (35.4)	51 (64.6)	0.08
> 60 years	28	13 (46.4)	15 (53.6)		5 (17.9)	23 (82.1)
Menopausal status
premenopause	51	28 (54.9)	23 (45.1)	0.82	16 (31.4)	35 (68.6)	0.91
postmenopause	56	32 (57.1)	24 (42.9)		17 (30.4)	39 (69.6)
Residual tumor
no residual tumor	56	31 (55.4)	25 (44.6)	0.87	20 (35.7)	36 (64.3)	0.25
residual tumor	51	29 (56.9)	22 (43.1)		13 (25.5)	38 (74.5)
Histology
mucinous	25	19 (76.0)	6 (24.0)	0.02	14 (56.0)	11 (44.0)	0.002
non-mucinous	82	41 (50.0)	41 (50.0)		19 (23.2)	63 (76.8)
Tumor grade
G1-2	53	31 (58.5)	22 (41.5)	0.62	21 (39.6)	32 (60.4)	0.05
G3	54	29 (53.7)	25 (46.3)		12 (22.2)	42 (77.8)
FIGO Staging
stage 1-2	54	30 (55.6)	24 (44.4)	0.91	20 (37.0)	34 (63.0)	0.16
stage 3-4	53	30 (56.6)	23 (43.4)		13 (24.5)	40 (75.5)
Response to first line	N = 88	n = 48	n = 40		n = 26	n = 62
chemotherapy				0.38			0.01
response	55	32 (58.2)	23 (41.8)		11 (20.0)	44 (80.0)
no response	33	16 (48.5)	17 (51.5)		15 (45.5)	18 (54.5)